Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593951 · ClinicalTrials.gov registry record
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)
A clinical trial of Progressive Myoclonus Epilepsy Type 1 and EPM1, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06593951 is a study of Progressive Myoclonus Epilepsy Type 1 and EPM1 that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06593951, a study of Progressive Myoclonus Epilepsy Type 1 and EPM1, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) is focused on gathering longitudinal clinical data as well as biological samples (blood and/or urine) from male and female patients, of all ages, who have a molecular diagnosis of EPM1or CSTB-null-related disease. Currently, there are no therapies that halt disease progression in any CSTB-related diseases, highlighting the urgency for translational research into this condition. The primary objective of the registry is to determine the natural history and genotype-phenotype correlations of disease-causing variants in EPM1 and CSTB-null-related disease.
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Childrens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2030-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06593951
The ClinicalTrials.gov registry entry for NCT06593951 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Progressive Myoclonus Epilepsy Type 1 appearing as the primary indexed condition, and to 0 interventions.
NCT06593951 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06593951 about?
NCT06593951 is a clinical study titled "Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)". The Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) is focused on gathering longitudinal clinical data as well as biological samples (blood and/or urine) from male and female patients, of all ages, who have a molecular diagnosis of EPM1or CSTB-null-related disease...
What is the current status of trial NCT06593951?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-10-10. Estimated completion is 2030-10-01.
What conditions does trial NCT06593951 study?
This clinical trial studies the following conditions: Progressive Myoclonus Epilepsy Type 1, EPM1, CSTB-related Disease, Myoclonus Epilepsies, Progressive, Unverricht-Lundborg Disease.
Who is sponsoring clinical trial NCT06593951?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06593951 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.